$0.88
-0.15 (-14.95%)
Open$1.04
Previous Close$1.03
Day High$1.07
Day Low$0.86
52W High$7.35
52W Low$0.25
Volume—
Avg Volume1.32M
Market Cap7.38M
P/E Ratio—
EPS$-2.25
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,146.6% upside
Current
$0.88
$0.88
Target
$19.68
$19.68
$12.72
$19.68 avg
$25.92
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 185.5K | 924.6K | 478.0K |
| Net Income | -27,172,981 | -121,912,676 | -25,168 |
| Profit Margin | -14,677.7% | -13,943.8% | -5.3% |
| EBITDA | -25,482,234 | -120,678,575 | -28,783 |
| Free Cash Flow | — | — | -23,138 |
| Rev Growth | -79.9% | -79.9% | +3.1% |
| Debt/Equity | 2.46 | 2.46 | 0.11 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $254.31 | +0.38% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $360.55 | +0.62% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.33 | -1.21% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $499.65 | +1.69% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $631.81 | -0.17% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $293.52 | +0.74% | 69.3 | 39.97B |